Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers Source: Eur Respir J 2002; 20: Suppl. 38, 88s Year: 2002
Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006
Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation Source: Eur Respir J 2001; 18: Suppl. 33, 483s Year: 2001
Concentration of vasoactive intestinal peptide (VIP) and substance P (SP) in bronchi of patients with mild to moderate bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005
Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008
Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 259s Year: 2002
Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009
VIP (vasoactive intestinal polypeptide) and vitamin C in the serum of COPD patients before and after therapy Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006
The vasoactive effects of helospectins I and II in vivo are not mediated by VIP and PACAP1-38 receptors or vasodilator prostaglandins Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
Vasoactive intestinal peptide (VIP) supresses ACE2- and TMPRSS2 expression in stimulated epithelial cells Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021
Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007
Protection of vasoconstriction and lung function impairment by endothelin-receptor blockers and vasoactive intestinal peptide (VIP) in isolated perfused rat lungs Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Neuropeptide regulation of secretion and inflammation in human airway gland serous cells Source: Eur Respir J, 55 (4) 1901386; 10.1183/13993003.01386-2019 Year: 2020
Effects of leukotriene receptor antagonists on airway mucus secretion Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001
TLR4 mediates LPS-induced mucus hypersecretion in rat airway Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007
Circulating vasoactive intestinal peptide for diagnosis of exacerbation of COPD Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015
The possible role of gastrin-releasing peptide on pulmonary fibrosis Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018
Pro-inflammatory cytokines stimulate airway mucus secretion in a rat model of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 520s Year: 2001
Club cell 10-kDa protein attenuates airway mucus hypersecretion and inflammation Source: Eur Respir J 2014; 44: 1002-1010 Year: 2014